Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Harvard Bioscience (HBIO) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Harvard Bioscience's Net Income towards Common Stockholders rose 7430.24% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.8 million, marking a year-over-year decrease of 27876.57%. This contributed to the annual value of -$12.4 million for FY2024, which is 26325.04% down from last year.
  • Per Harvard Bioscience's latest filing, its Net Income towards Common Stockholders stood at -$1.2 million for Q3 2025, which was up 7430.24% from -$2.3 million recorded in Q2 2025.
  • Harvard Bioscience's 5-year Net Income towards Common Stockholders high stood at $2.4 million for Q2 2022, and its period low was -$50.3 million during Q1 2025.
  • Its 5-year average for Net Income towards Common Stockholders is -$4.2 million, with a median of -$1.2 million in 2023.
  • Over the last 5 years, Harvard Bioscience's Net Income towards Common Stockholders had its largest YoY gain of 69390.24% in 2022, and its largest YoY loss of 190294.12% in 2022.
  • Harvard Bioscience's Net Income towards Common Stockholders (Quarter) stood at $590000.0 in 2021, then plummeted by 466.78% to -$2.2 million in 2022, then increased by 15.99% to -$1.8 million in 2023, then skyrocketed by 102.75% to $50000.0 in 2024, then plummeted by 2568.0% to -$1.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$1.2 million for Q3 2025, versus -$2.3 million for Q2 2025 and -$50.3 million for Q1 2025.